Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ465466-1,14
KB738,5739,5-0,67
PKN66,9467,06-2,52
Msft1,25
Nokia3,663,670,96
IBM-1,38
Daimler AG40,0740,0951,73
PFE2,33
26.02.2020 23:11:00
Indexy online
AD Index online
select
AD Index online
 

  • 26.02.2020 17:35:30
Bristol Myers (BMY.DE, Xetra)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
58,10 1,25 0,72 672 665
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 26.02.2020
Popis společnosti
Obecné informace
Název společnostiBristol-Myers Squibb Co
TickerBMY
Kmenové akcie:Ordinary Shares
RICBMY
ISINUS1101221083
Prioritní akcieConv. Pref. Shrs
TickerBMYMP
RICBMYMP.PK
Poslední známé roční výsledky31.12.2019
Poslední známé čtvrtletní výsledky31.12.2019
Počet zaměstnanců k 31.12.2018 23 300
Akcie v oběhu k 20.11.20192 344 194 343
MěnaUSD
Konstituent indexůS&P 500
Kontaktní informace
Ulice430 E 29th St Fl 14
MěstoNEW YORK
PSČ10016-8367
ZeměUnited States
Kontatní osobaJohn Elicker
Funkce kontaktní osobySenior Vice President - Corporate Affairs and Investor Relations
Telefon12 125 464 000
Fax13026555049
Kontatní telefon16 092 524 611

Business Summary: Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2019, Bristol-Myers Squibb Co revenues increased 16% to $26.15B. Net income before extraordinary items decreased 31% to $3.44B. Revenues reflect Net product sales increase of 17% to $25.17B. Net income was offset by Other Non Rec. I/E - Non Business Activ. decrease from $27M (income) to $1.6B (expense), Research increase of 17% to $5.92B (expense), Interest Expense increase from $183M to $656M (expense).
Odvětvová klasifikace
TRBC2012Pharmaceuticals - NEC
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSDrug, Drug Proprietaries and Druggists' Sundries Wholesalers
SICPharmaceutical Preparations
SICPharmaceutical Preparations
SICCommercial Physical Research
SICDrugs/proprietaries/sundries



  • Poslední aktualizace: 26.02.2020
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Chief Executive OfficerGiovanni Caforio5402.05.201719.10.2011
Chief Financial Officer, Executive Vice President - Global Business OperationsCharles Bancroft5901.01.2010
Chief Human Resource Officer, Senior Vice PresidentAnn Judge53
Executive Vice President, General CounselSandra Leung5801.01.2002
Executive Vice President and Chief Commercial OfficerChristopher Boerner4828.08.201828.08.2018
Executive Vice President - Corporate AffairsKathryn Metcalfe-06.01.202006.01.2020
Chief Information Officer, Senior Vice PresidentPaul von Autenried5701.01.2011
Senior Vice President, Chief Compliance Officer and Ethics OfficerAdam Dubow5201.01.2018
Senior Vice President, Corporate ControllerKaren Santiago4815.02.201815.02.2018
Senior Vice President - Corporate Affairs and Investor RelationsJohn Elicker5901.01.2012